Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment

Koichi Node, Teruo Inoue*, Valentin Boyko, Ilan Goldberg, Enrique Z. Fisman, Yehuda Adler, Ehud Schwammenthal, Zipora Matas, Solomon Behar, Alexander Tenenbaum

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on ProBNP level in patients with pre-existing CAD and advanced functional capacity impairment. Methods: Metabolic and inflammatory parameters were analyzed from stored frozen serum samples obtained from 108 patients enrolled in the Bezafibrate Infarction Prevention (BIP) Study. They presented with New York Heart Association (NYHA) functional class III, comprising 58 patients in the bezafibrate group and 50 in the placebo groups, and completed a 2-year prospective, double-blind, placebo-controlled follow-up. Results: During follow-up ProBNP level did not change significantly in the placebo group, whereas it increased slightly in the bezafibrate group, which was older and with lower baseline ProBNP values. No significant differences between the groups were found for ProBNP levels after 2 year of follow-up. Analysis-of-covariance (ANCOVA) -taking into account age and baseline ProBNP level- showed that bezafibrate was not associated with longitudinal ProBNP changes during the follow-up period (p = 0.3). Conclusion: Long-term treatment by bezafibrate was not associated with longitudinal ProBNP changes in patients with pre-existing CAD and advanced functional capacity impairment.

Original languageEnglish
Article number5
JournalCardiovascular Diabetology
Volume8
DOIs
StatePublished - 28 Jan 2009

Funding

FundersFunder number
Kimura Foundation
Japan Cardiovascular Research Foundation
Ministry of Education, Culture, Sports, Science and Technology

    Fingerprint

    Dive into the research topics of 'Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment'. Together they form a unique fingerprint.

    Cite this